Baseline characteristics of study populations.
| Characteristics | CHOP-like (n = 51) | CHOPR-like | ||
|---|---|---|---|---|
| With IFN (n = 20) | Without IFN (n = 31) | Total (n = 51) | ||
| Age, median (range, year) | 55 (19-79) | 60 (28-77) | 55 (18-79) | 56.5 (18-79) |
| Sex | ||||
| Female | 43.1% | 45.0% | 35.5% | 39.2% |
| Male | 56.9% | 55.0% | 64.5% | 60.8% |
| Performance status | ||||
| ≤ 2 | 74.5% | 70.0% | 77.4% | 74.5% |
| > 2 | 25.5% | 30.0% | 22.6% | 25.5% |
| Ann Arbor clinical stage | ||||
| I/II | 33.3% | 10.0% | 25.8% | 19.6% |
| III/IV | 66.7% | 90.0% | 74.2% | 80.4% |
| LDH level | ||||
| Normal | 41.2% | 20.0% | 29.0% | 25.5% |
| Elevated | 58.8% | 80.0% | 71.0% | 74.5% |
| β2-MG | ||||
| Normal | 39.2% | 35.0% | 38.7% | 37.3% |
| Elevated | 60.8% | 65.0% | 61.3% | 62.5% |
| Extranodal site | ||||
| ≤ 1 | 84.3% | 60.0% | 74.2% | 68.6% |
| > 1 | 15.7% | 40.0% | 25.8% | 31.4% |
| Bulky disease (≥ 5 cm) | ||||
| Yes | 15.7% | 20.0% | 19.4% | 19.6% |
| No | 84.3% | 80.0% | 80.6% | 80.4% |
| IPI | ||||
| 0-1 | 41.2% | 0 | 19.4% | 11.8% |
| ≥ 2 | 58.8% | 100% | 80.6% | 88.2% |
| Bcl-2 | ||||
| Positive | 31.4% | 50.0% | 54.8% | 52.9% |
| Negative | 68.6% | 50.0% | 45.2% | 47.1% |